Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-P4 alpelisib in PIK3CA-related overgrowth spectrum
NL-OMON59073Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alpelisib in PIK3CA-related overgrowth spectrum (PROS), sponsored by Novartis. Primary endpoint: Confirmed objective response rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
alpelisib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)
Beyond the preview
Go deeper on NL-OMON59073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59073.